Lasinavir
![]() | |
Names | |
---|---|
IUPAC name
tert-butyl N-[(2S,3S,5R)-3-hydroxy-6-[[(2S)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate | |
Identifiers | |
175385-62-3 ![]() | |
ChemSpider | 408297 ![]() |
Jmol interactive 3D | Image |
PubChem | 464372 |
UNII | 0QGV8237I3 ![]() |
| |
| |
Properties | |
C35H53N3O9 | |
Molar mass | 659.81 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
![]() ![]() ![]() | |
Infobox references | |
Lasinavir (INN,[1] previously known as BMS-234475 and CGP-61755) is an experimental peptidomimetic protease inhibitor researched by Novartis and Bristol-Myers Squibb as a treatment for HIV infection. It was originally discovered by Novartis at Basel (Switzerland).[2] Its investigation was terminated after Phase I on October 09, 2002.[3]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names (Rec. INN): List 38" (PDF). WHO Drug Information (World Health Organization) 11 (3): 170. 1997. Retrieved 25 November 2015.
- ↑ B2 US patent 7348345 B2, James Patrick Dunn, Steven Swallow, Zachary Kevin Sweeney, "Nonnucleoside reverse transcriptase inhibitors", issued 2008-08-02
- ↑ "Drug Profile: Lasinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 25 November 2015.
This article is issued from Wikipedia - version of the Tuesday, March 22, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.